The role of the serum tube agglutination test in the monitoring of human brucellosis: evaluation of post-treatment SAT titers.


Journal

Revista da Associacao Medica Brasileira (1992)
ISSN: 1806-9282
Titre abrégé: Rev Assoc Med Bras (1992)
Pays: Brazil
ID NLM: 9308586

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 06 05 2022
accepted: 23 05 2022
entrez: 13 10 2022
pubmed: 14 10 2022
medline: 18 10 2022
Statut: ppublish

Résumé

Positive results of the serum tube agglutination test that persist after treatment may be interpreted by clinicians as treatment failures. Therefore, our study examined the value of serum tube agglutination test in demonstrating treatment success. In this retrospective study conducted at a single center, the pre- and post-treatment serum tube agglutination test titers of patients diagnosed with brucellosis were compared. The end-of-treatment serum tube agglutination test titer was negative in 24 (18%) of 139 patients diagnosed with brucellosis. The most common complaints of the patients were fever (78.4%), chills (88.5%), sweating (84.9%), anorexia (79.1%), and arthralgia (63.3%). The rate of positive blood culture before the treatment was 68.3%. The absence of fever (p=0.005) and arthralgia (p=0.024) and the pretreatment serum tube agglutination test titer of <1/160 (p=0.014) were significant markers of serological cure. Although serum tube agglutination test is an effective and very successful test in the diagnosis of brucellosis, our study shows that serum tube agglutination test is not useful in demonstrating the treatment success of human brucellosis in the early post-treatment period.

Identifiants

pubmed: 36228254
pii: S0104-42302022000901234
doi: 10.1590/1806-9282.20220269
pmc: PMC9575016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1234-1239

Références

J Infect Dis. 1988 May;157(5):918-24
pubmed: 3361155
N Engl J Med. 2005 Jun 2;352(22):2325-36
pubmed: 15930423
Clin Lab. 2020 Sep 1;66(9):
pubmed: 32902225
J Infect. 2000 Jan;40(1):59-63
pubmed: 10762113
Med Sci Monit. 2005 Nov;11(11):MT69-74
pubmed: 16258407
J Clin Microbiol. 1999 Oct;37(10):3245-8
pubmed: 10488186
J Infect Dis. 1989 Feb;159(2):219-25
pubmed: 2915152
Mikrobiyol Bul. 2003 Oct;37(4):261-7
pubmed: 14748263
Clin Infect Dis. 1996 Mar;22(3):446-55
pubmed: 8852961
PLoS Negl Trop Dis. 2018 Oct 18;12(10):e0006874
pubmed: 30335748
Int J Infect Dis. 2010 Mar;14(3):e250-3
pubmed: 19648045
Eur J Clin Microbiol Infect Dis. 2022 May;41(5):793-801
pubmed: 35364783
J Clin Microbiol. 1980 Jun;11(6):691-3
pubmed: 6776139
Infection. 2009 Feb;37(1):67-9
pubmed: 19139815
Medicine (Baltimore). 1996 Jul;75(4):195-211
pubmed: 8699960
J Clin Microbiol. 2002 Jun;40(6):2313
pubmed: 12037121

Auteurs

Betul Copur (B)

Haseki Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology - Istanbul, Turkey.

Ozgur Pasa (O)

Bitlis Tatvan State Hospital, Department of Clinical Microbiology - Bitlis, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH